NASDAQ:ALKS - Alkermes Stock Price, Forecast & News

Alkermes trades on the NASDAQ under the ticker symbol "ALKS."

Alkermes Plc (NASDAQ:ALKS) announced its earnings results on Thursday, February, 13th. The company reported $0.83 earnings per share for the quarter, beating the Thomson Reuters' consensus estimate of $0.65 by $0.18. The business had revenue of $412.70 million for the quarter, compared to the consensus estimate of $404.45 million. Alkermes had a negative net margin of 16.79% and a positive return on equity of 1.58%. The business's revenue for the quarter was up 30.7% on a year-over-year basis. During the same quarter in the prior year, the firm posted $0.34 earnings per share. View Alkermes' Earnings History.

Alkermes is scheduled to release their next quarterly earnings announcement on Thursday, April 23rd 2020. View Earnings Estimates for Alkermes.

Alkermes updated its FY20 earnings guidance on Thursday, February, 13th. The company provided earnings per share guidance of $0.25 to $0.43 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $0.52. The company issued revenue guidance of $1.03 billion to $1.08 billion, compared to the consensus revenue estimate of $1.06 billion.

11 brokerages have issued 1-year price targets for Alkermes' stock. Their forecasts range from $19.00 to $28.00. On average, they anticipate Alkermes' stock price to reach $23.00 in the next twelve months. This suggests a possible upside of 23.2% from the stock's current price. View Analyst Price Targets for Alkermes.

11 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Alkermes in the last year. There are currently 1 sell rating, 9 hold ratings and 1 buy rating for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Alkermes.

News articles about ALKS stock have been trending somewhat negative recently, InfoTrie Sentiment Analysis reports. The research firm scores the sentiment of press coverage by analyzing more than six thousand news and blog sources. The firm ranks coverage of public companies on a scale of negative five to five, with scores nearest to five being the most favorable. Alkermes earned a media sentiment score of -1.4 on InfoTrie's scale. They also assigned press coverage about the company a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an effect on the company's share price in the next several days. View News Stories for Alkermes.

Alkermes saw a increase in short interest during the month of January. As of January 15th, there was short interest totalling 5,250,000 shares, an increase of 10.5% from the December 31st total of 4,750,000 shares. Based on an average daily volume of 1,570,000 shares, the short-interest ratio is currently 3.3 days. Currently, 3.4% of the company's stock are short sold. View Alkermes' Current Options Chain.

Some companies that are related to Alkermes include Amgen (AMGN), Gilead Sciences (GILD), Celgene (CELG), Vertex Pharmaceuticals (VRTX), Biogen (BIIB), Regeneron Pharmaceuticals (REGN), Alexion Pharmaceuticals (ALXN), Seattle Genetics (SGEN), Incyte (INCY), BioMarin Pharmaceutical (BMRN), Alnylam Pharmaceuticals (ALNY), EXACT Sciences (EXAS), Neurocrine Biosciences (NBIX), Ionis Pharmaceuticals (IONS) and Exelixis (EXEL).

Based on aggregate information from My MarketBeat watchlists, some companies that other Alkermes investors own include AbbVie (ABBV), Netflix (NFLX), Celgene (CELG), NVIDIA (NVDA), Alibaba Group (BABA), Gilead Sciences (GILD), Intel (INTC), Starbucks (SBUX), Pfizer (PFE) and Advanced Micro Devices (AMD).

Alkermes' stock is owned by a variety of of institutional and retail investors. Top institutional investors include Renaissance Technologies LLC (4.21%), State Street Corp (2.95%), FMR LLC (1.78%), First Trust Advisors LP (1.78%), AQR Capital Management LLC (1.22%) and Goldman Sachs Group Inc. (0.98%). Company insiders that own Alkermes stock include David Joseph Gaffin, David W Anstice, Floyd E Bloom, James M Frates, Michael J Landine, Nancy Wysenski, Paul J Mitchell and Richard F Pops. View Institutional Ownership Trends for Alkermes.

ALKS stock was sold by a variety of institutional investors in the last quarter, including FMR LLC, UBS Asset Management Americas Inc., State Street Corp, Korea Investment CORP, UBS Group AG, Swiss National Bank, AQR Capital Management LLC and Bank of New York Mellon Corp. Company insiders that have sold Alkermes company stock in the last year include David Joseph Gaffin, Michael J Landine, Paul J Mitchell and Richard F Pops. View Insider Buying and Selling for Alkermes.

ALKS stock was acquired by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC, Krensavage Asset Management LLC, Goldman Sachs Group Inc., Russell Investments Group Ltd., Jacobs Levy Equity Management Inc., Connor Clark & Lunn Investment Management Ltd., Bank of Montreal Can and First Trust Advisors LP. View Insider Buying and Selling for Alkermes.

Shares of ALKS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of ALKS stock can currently be purchased for approximately $18.67.

Alkermes has a market capitalization of $2.95 billion and generates $1.17 billion in revenue each year. The company earns $-196,620,000.00 in net income (profit) each year or $0.07 on an earnings per share basis. Alkermes employs 2,300 workers across the globe.View Additional Information About Alkermes.

The official website for Alkermes is http://www.alkermes.com/.

Alkermes' mailing address is 1 BURLINGTON ROAD CONNAUGHT HOUSE, DUBLIN L2, DUBLIN 4. The company can be reached via phone at 353-1772-8000 or via email at [email protected]